ライフサイエンスコーパス: TNF-related apoptosis-inducing ligand

1 nd TNF superfamily proteins 2, 7, 9, and 10 (TNF-related apoptosis-inducing ligand).

2 ate cells sensitizes to cell death by TRAIL (TNF-related apoptosis-inducing ligand).

3 uced by tumor necrosis factor (TNF) alpha or TNF-related apoptosis-inducing ligand.

4 nse to death receptor ligands, TNF-alpha and TNF-related apoptosis-inducing ligand.

5 tumor necrosis factor receptor 1 (2.29), and TNF-related apoptosis-inducing ligand (0.34).

6 also called TRAIL for tumor necrosis factor (TNF)-related apoptosis-inducing ligand [2]) belongs to t

7 Apo-2 ligand (Apo-2L)/TNF-related apoptosis-inducing ligand, a new member of t

8 , accompanied with upregulated expression of TNF-related apoptosis-inducing ligand and activation of

9 Also, PS-341 enhanced TRAIL (TNF-related apoptosis-inducing ligand) and TNFalpha (tum

10 other contexts, interactions between TRAIL (TNF-related apoptosis-inducing ligand/Apo-2L) and its re

11 of human recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand/Apo2 ligand (TRAI

12 so bind to other TNF family members, such as TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL

13 Apoptosis ligand 2 tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) bel

14 Apo2 ligand/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) mai

15 We have previously shown that Apo2 ligand/TNF-Related apoptosis inducing ligand (Apo2L/TRAIL) indu

16 ein comprising the ectodomain of Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) has

17 E-selectin adhesion protein and Apo2L/TRAIL (TNF-related apoptosis-inducing ligand) apoptosis ligand

18 n of p38alpha signaling and up-regulation of TNF-related apoptosis-inducing ligand are detected in ap

19 up-regulation of Fas, death receptor 3, and TNF-related apoptosis-inducing ligand by CD30 indicates

20 ion, we show that murine IFN-gamma and human TNF-related apoptosis-inducing ligand can be displayed o

21 ls to apoptosis induced by TNF-family member TNF-related apoptosis-inducing ligand, consistent with a

22 MYC, up-regulation of surface levels of the TNF-related apoptosis-inducing ligand death receptor 5,

23 ta) as a gene whose inactivation potentiates TNF-related apoptosis-inducing ligand death receptor-med

24 mutant unable to restrict expression of the TNF-related apoptosis-inducing ligand death receptors (T

25 TRAIL (TNF-related apoptosis-inducing ligand) death receptors D

26 ytosis and apoptotic signaling downstream of TNF-related apoptosis-inducing ligand-death receptor (TR

27 The mAb 4H6 (IgG1) competed with Apo2L/TNF-related apoptosis-inducing ligand (DR4's ligand) for

28 tory markers tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand in irradiated skin

29 osis induced by the cell death ligand TRAIL (TNF-related apoptosis-inducing ligand) in human cancer c

30 arabine (Ara-C), etoposide, or Apo-2L/TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis

31 crosis factor-induced apoptosis but not from TNF-related apoptosis-inducing ligand-induced apoptosis.

32 l death, with no effect seen on TNF-alpha or TNF-related apoptosis-inducing ligand-induced apoptosis.

33 TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis

34 mbination with TRAIL (tumor necrosis factor [TNF]-related apoptosis-inducing ligand) induces a synerg

35 TRAIL, the TNF-related apoptosis-inducing ligand, induces apoptosis

36 , tumor necrosis factor alpha (TNFalpha) and TNF-related apoptosis-inducing ligand inhibit overall tr

37 Finally, SiAd expressing TNF-related apoptosis-inducing ligand inhibited tumor gr

38 Furthermore, the cytokines Fas ligand, TNF-related apoptosis-inducing ligand, interleukin (IL)-

39 TRAIL (TNF-related apoptosis-inducing ligand) is a member of th

40 TRAIL (TNF-related apoptosis-inducing ligand) is a potent induc

41 TRAIL (TNF-related apoptosis-inducing ligand) is a potential an

42 TRAIL (tumor necrosis factor [TNF]-related apoptosis-inducing ligand) is a molecule th

43 TNF-alpha (Tumor Necrosis Factor) or TRAIL (TNF-Related Apoptosis-Inducing Ligand); is an extremely

44 s mediated by TRAIL (tumour necrosis factor (TNF)-related apoptosis-inducing ligand) it is common for

45 substantial increase in TNF-alpha and TRAIL (TNF-related apoptosis-inducing ligand)-mediated apoptosi

46 Fs) resulted in resistance to TNF-alpha- and TNF-related apoptosis-inducing ligand-mediated apoptosis

47 688 induced an expansion of immunoregulatory TNF-related apoptosis-inducing ligand(+) NK cells and de

48 T-cells; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; OPG, osteoprotege

49 gonist rituximab in combination with rhApo2L/TNF-related apoptosis inducing ligand or fenretinide, a

50 pression/secretion and function of NKp30 and TNF-related apoptosis-inducing ligand, particularly amon

51 ors: tumor necrosis factor receptor (TNF-R), TNF-related apoptosis-inducing ligand receptor (TRAIL-R)

52 Herein we show that TNF-related apoptosis-inducing ligand receptor (TRAIL-R)

53 d in NS1-immunized rabbits crossreacted with TNF-related apoptosis-inducing ligand receptor 1 (death

54 ic Fas-associated protein with death domain, TNF-related apoptosis-inducing ligand receptor, or Fas s

55 Affected receptors include Fas, TRAIL (TNF-related apoptosis-inducing ligand) receptor 1 (TR1),

56 ew member of this family, TRICK2, the TRAIL (TNF-related apoptosis-inducing ligand) receptor inducer

57 r necrosis factor (TNF)-alpha receptor 1, or TNF-related apoptosis-inducing ligand receptors (DR4 and

58 eceptor (TNFR) superfamily, including TNFR1, TNF-related apoptosis-inducing ligand receptors (TRAIL-R

59 we evaluated two drug formulations of TRAIL (TNF-related apoptosis inducing ligand): soluble and anch

60 soluble extracellular domain of proapoptotic TNF-related apoptosis-inducing ligand (sTRAIL) would mar

61 multimeric variant of the known anti-cancer TNF-related apoptosis-inducing ligand (sTRAIL).

62 anzyme degranulation pathway and the TNF/Fas/TNF-related apoptosis-inducing ligand superfamily of apo

63 ng adenovirus E1A and tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) in a repl

64 udies, treatment with tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL, also know

65 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (Apo2 lig

66 Ligation of DR5 by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activates

67 f combining CD437 and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas l

68 apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and one o

69 that plasma levels of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) are eleva

70 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces a

71 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces a

72 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces a

73 late with PML NBs and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induction

74 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a cyto

75 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a memb

76 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a memb

77 Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL) is a memb

78 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a memb

79 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a memb

80 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a TNF

81 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is an imm

82 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known

83 Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-al

84 apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNFalp

85 that miR-494 induced Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) resistanc

86 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selective

87 Because tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selective

88 s DR5, a receptor for tumor-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) that is e

89 and the potential of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), clinical

90 diators and products--tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas liga

91 aurosporine (STS) and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), respecti

92 ic pathways driven by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), thereby

93 sms in genes encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF- alp

94 in and inhibits tumor necrosis factor-alpha (TNF)-related apoptosis-inducing ligand (TRAIL)-induced a

95 tion of PDC-dependent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated

96 h2-related cytokines, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-R2/DR5, a

97 death is mediated by tumour-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

98 osis-inducing protein tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

99 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/APO-2L is

100 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2 liga

101 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, APO-2L) i

102 ted increased urinary tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo-2L) le

103 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) is

104 We use the response to TNF-related apoptosis inducing ligand (TRAIL) and a new

105 nfected with HIV, HIV infection up-regulates TNF-related apoptosis inducing ligand (TRAIL) and death-

106 kappaB ligand (RANKL), TNF-alpha, CD95L, and TNF-related apoptosis inducing ligand (TRAIL) in T cell

107 ng leukocytes to present the cancer-specific TNF-related apoptosis inducing ligand (TRAIL) on their s

108 nce had significantly higher serum levels of TNF-related apoptosis inducing ligand (TRAIL), compared

109 DR5 promotes TNF-related apoptosis inducing ligand (TRAIL)-induced ap

110 iologically relevant death ligands including TNF-related apoptosis inducing ligand (TRAIL).

111 e T cells used the cognate proteins FasL and TNF-related apoptosis-inducing ligand (TRAIL) (but not T

112 The cytokine TNF-related apoptosis-inducing ligand (TRAIL) and its ce

113 Since the discovery of TNF-related apoptosis-inducing ligand (TRAIL) and its ne

114 past year, knowledge of the system involving TNF-related apoptosis-inducing ligand (TRAIL) and its re

115 gnificantly increases the expression of both TNF-related apoptosis-inducing ligand (TRAIL) and of the

116 mic compound (Smac-mimic), which potentiates TNF-related apoptosis-inducing ligand (TRAIL) and tumor

117 is upregulated in response to treatment with TNF-related apoptosis-inducing ligand (TRAIL) and tumor

118 uclear factor-kappaB (RANK)/RANK ligand, and TNF-related apoptosis-inducing ligand (TRAIL) Apo-2L/TRA

119 s factor (TNF) family of cytokines, FasL and TNF-related apoptosis-inducing ligand (TRAIL) are known

120 tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand (TRAIL) are produc

121 the thiazolidinedione troglitazone (TZD) and TNF-related apoptosis-inducing ligand (TRAIL) can induce

122 TNF-related apoptosis-inducing ligand (TRAIL) can select

123 6 protein, which restricts expression of the TNF-related apoptosis-inducing ligand (TRAIL) death rece

124 t the induction of the proapoptotic molecule TNF-related apoptosis-inducing ligand (TRAIL) during rea

125 fter HIV-1 exposure, which in turn regulates TNF-related apoptosis-inducing ligand (TRAIL) expression

126 Additionally, physapubescin synergizes with TNF-related apoptosis-inducing ligand (TRAIL) for marked

127 TNF-related apoptosis-inducing ligand (TRAIL) has been s

128 The TNF-related apoptosis-inducing ligand (TRAIL) has well-d

129 TNF-related apoptosis-inducing ligand (TRAIL) holds prom

130 the main intrahepatic lymphocytes expressing TNF-related apoptosis-inducing ligand (TRAIL) in CHB.

131 ed apoptosis partly through the induction of TNF-related apoptosis-inducing ligand (TRAIL) in pancrea

132 mined the role of the TNF superfamily member TNF-related apoptosis-inducing ligand (TRAIL) in S. pneu

133 describe an improved approach to delivering TNF-related apoptosis-inducing ligand (TRAIL) in vivo in

134 The TNF-related apoptosis-inducing ligand (TRAIL) induces ap

135 TNF-related apoptosis-inducing ligand (TRAIL) is a death

136 TNF-related apoptosis-inducing ligand (TRAIL) is a membe

137 TNF-related apoptosis-inducing ligand (TRAIL) is a more

138 TNF-related apoptosis-inducing ligand (TRAIL) is a poten

139 TNF-related apoptosis-inducing ligand (TRAIL) is a poten

140 TNF-related apoptosis-inducing ligand (TRAIL) is able to

141 previously shown that endogenously expressed TNF-related apoptosis-inducing ligand (TRAIL) is require

142 Because TNF-related apoptosis-inducing ligand (TRAIL) kills cell

143 Enhanced expression of TNFSF10 or TNF-related apoptosis-inducing ligand (TRAIL) mRNA in un

144 ministration of dTAT NP-encapsulated AT2R or TNF-related apoptosis-inducing ligand (TRAIL) pDNA marke

145 nd (RANKL), TNF-alpha, Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) play pivot

146 TNF-related apoptosis-inducing ligand (TRAIL) promotes i

147 g agents, i.e. monoclonal antibodies against TNF-related apoptosis-inducing ligand (TRAIL) receptor 1

148 family of receptors such as Fas/CD95 and the TNF-related apoptosis-inducing ligand (TRAIL) receptors

149 t the extracellular domain of the four known TNF-related apoptosis-inducing ligand (TRAIL) receptors

150 (with high affinity) to the death domain of TNF-related apoptosis-inducing ligand (TRAIL) receptors,

151 ur necrosis factor receptor 1 (TNFR1), CD95, TNF-related apoptosis-inducing ligand (TRAIL) receptors,

152 he TNFR superfamily, such as Fas, TNFR1, and TNF-related apoptosis-inducing ligand (TRAIL) receptors.

153 ribed to enhance cell survival and to induce TNF-related apoptosis-inducing ligand (TRAIL) resistance

154 TNF-related apoptosis-inducing ligand (TRAIL) selectivel

155 TNF-related apoptosis-inducing ligand (TRAIL) shows prom

156 sduce apoptotic signals upon binding soluble TNF-related apoptosis-inducing ligand (TRAIL) that, like

157 h tumor necrosis factor alpha (TNFalpha) and TNF-related apoptosis-inducing ligand (TRAIL) to potentl

158 The TNF-related apoptosis-inducing ligand (TRAIL) triggers a

159 TNF-related apoptosis-inducing ligand (TRAIL) was initia

160 TLY012 is an engineered human TNF-related apoptosis-inducing ligand (TRAIL) which indu

161 Recent evidence suggests that TNF-related apoptosis-inducing ligand (TRAIL), a death-i

162 TNF-related apoptosis-inducing ligand (TRAIL), a member

163 The observation that TNF-related apoptosis-inducing ligand (TRAIL), a member

164 21(WAF1) or death receptor 5 (KILLER/DR5) of TNF-related apoptosis-inducing ligand (TRAIL), and induc

165 L2, tumor necrosis factor alpha (TNF-alpha), TNF-related apoptosis-inducing ligand (TRAIL), and inter

166 ligand (L), CD27L, CD30L, OX40L, 4-1BBL, and TNF-related apoptosis-inducing ligand (TRAIL), but not C

167 In H460 cells, significant release of TNF-related apoptosis-inducing ligand (TRAIL), but not T

168 phenotype defined by increased expression of TNF-related apoptosis-inducing ligand (TRAIL), CD38, and

169 e to tumor necrosis factor alpha (TNFalpha), TNF-related apoptosis-inducing ligand (TRAIL), etoposide

170 Recent reports demonstrate that TNF-related apoptosis-inducing ligand (TRAIL), interacti

171 in (OPG), a soluble receptor of the cytokine TNF-related apoptosis-inducing ligand (TRAIL), is secret

172 , vascular endothelial growth factor (VEGF), TNF-related apoptosis-inducing ligand (TRAIL), TNF-alpha

173 1 and 2, active caspase 8, active caspase 3, TNF-related apoptosis-inducing ligand (TRAIL), TRAIL-R(D

174 as, TNF receptor-1 (TNFR1), or receptors for TNF-related apoptosis-inducing ligand (TRAIL), we invest

175 ent member of this family of proteins [e.g., TNF-related apoptosis-inducing ligand (TRAIL), which ind

176 sitive to killing by the proapoptotic ligand TNF-related apoptosis-inducing ligand (TRAIL), which is

177 ions, metastatic melanoma cell lines undergo TNF-related apoptosis-inducing ligand (TRAIL)- and tumor

178 at protects human colon carcinoma cells from TNF-related apoptosis-inducing ligand (TRAIL)-induced ap

179 Therapeutic agents that activate TNF-related apoptosis-inducing ligand (TRAIL)-induced ap

180 ed to demonstrate the complete inhibition of TNF-related apoptosis-inducing ligand (TRAIL)-induced ap

181 y, miR-25 was shown to protect cells against TNF-related apoptosis-inducing ligand (TRAIL)-induced ap

182 For TNF-related apoptosis-inducing ligand (TRAIL)-mediated a

183 tosis was also observed in 17AAG-treated and TNF-related apoptosis-inducing ligand (TRAIL)-treated ca

184 to cisplatin or cisplatin combined with the TNF-related apoptosis-inducing ligand (TRAIL).

185 thus blocking apoptosis initiated by Fas and TNF-related apoptosis-inducing ligand (TRAIL).

186 ed cells to apoptosis induced by TNF and the TNF-related apoptosis-inducing ligand (TRAIL).

187 id arthritis express receptors that can bind TNF-related apoptosis-inducing ligand (TRAIL).

188 c (AdsDR5), which is capable of neutralizing TNF-related apoptosis-inducing ligand (TRAIL).

189 agonistic anti-Fas monoclonal antibody, and TNF-related apoptosis-inducing ligand (TRAIL).

190 and radiotherapy and biologicals, including TNF-related apoptosis-inducing ligand (TRAIL).

191 ensitivity to tumor necrosis factor (TNF) or TNF-related apoptosis-inducing ligand (TRAIL).

192 tant to the novel selective cytotoxic agent, TNF-related apoptosis-inducing ligand (TRAIL).

193 of natural killer (NK) cell killing through TNF-related apoptosis-inducing ligand (TRAIL).

194 and an IFN-dependent elevation of macrophage TNF-related apoptosis-inducing ligand (TRAIL).

195 ls were directly linked to the expression of TNF-related apoptosis-inducing ligand (TRAIL).

196 mming, partly because of the upregulation of TNF-related apoptosis-inducing ligand (TRAIL).

197 tumor necrosis factor alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand (TRAIL).

198 mulatory effects, including the induction of TNF-related apoptosis-inducing ligand (TRAIL)/Apo-2L on

199 Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L are

200 tosis induced by the TNF-alpha family member TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L.

201 contributes to CD4+ T cell apoptosis by the TNF-related apoptosis-inducing ligand (TRAIL)/death rece

202 TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) has

203 pa B activity and potentiate the activity of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L), dex

204 the chemical inhibitor wortmannin increased TNF-related apoptosis-inducing ligand (TRAIL; Apo2) mRNA

205 We now show that the binding of TNF-related, apoptosis-inducing ligand (TRAIL) to its ce

206 ctivated by the death receptor pathway, is a TNF-related, apoptosis-inducing ligand (TRAIL)-induced l

207 ated killing express the death receptor DR5 (TNF-related apoptosis-inducing ligand [TRAIL] receptor 2

208 or that is most closely related to mammalian TNF-related apoptosis-inducing ligand [TRAIL] receptors)

209 For TRAIL (TNF-related apoptosis-inducing ligand) variability manif

210 inducible nitric oxide synthase, IL-23, and TNF-related apoptosis-inducing ligand were present in IF

211 lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis inducing ligand; while cancer cell